The following is a summary of “Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

Financial writer bullish on Synopsys, citing leadership in EDA software, strong financial performance, potential upside, and ...

Writing in his Daily Record column, Scottish Labour leader Anas Sarwar says the SNP will waste the £5.2bn given to it by the ...

Synopsys, Inc. (NASDAQ:SNPS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Ratings reports. One ...

In the closing of the recent trading day, Synopsys (SNPS) stood at $525.48, denoting a -0.17% change from the preceding trading day.

A new study finds differences in spending on long-term services and supports (LTSS) between people with dual eligibility for ...

Synopsys Inc. closed 16.37% short of its 52-week high of $629.38, which the company reached on February 22nd.

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...

SG Americas Securities LLC lessened its holdings in Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 97.9% during the fourth ...